Filer Snapshot

BB BIOTECH AG

CIK 0000924223. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

59

Latest filing

15 May 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2019. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

IONS

$627.04M reported value

Open holding

13D/G large stake

MGNX

01 Jun 2025 · 0% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Form 13F

13F-NT filed on 15 May 2026 for CIK 0000924223.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

AGIO MGNX BDTX SAGE ESPR
How to read these SEC ownership signals
  • Read each filing family separately: 13F portfolios, 13D/G large stakes, and Forms 3/4/5 owner positions answer different SEC disclosure questions.
  • Open the linked research path when you need the filing, CIK, issuer, or CUSIP trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
Schwertstrasse 6, Schaffhausen, 8200
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
Switzerland
Fiscal year end
31 December

Filer intelligence

What SEC filings say about BB BIOTECH AG

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $3.98B across 35 reported holdings for Q1 2019.
  • Largest parsed 13F holding: IONS at $627.04M.
  • 5 recent 13D/G stake rows found; top row is MGNX at 0% ownership.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 35 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2019 - 13 May 2019

Top 5 concentration

43%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$1.69B

Compared with $3.98B total 13F value.

Top 5 net change

-$109.56M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: CRSP · Largest trim: IONS

IONS INCY NBIX VRTX SAGE Other holdings

IONS

15.8%

Ionis Pharmaceuticals Inc.

$627.04M

INCY

7.8%

Incyte Corp.

$311.36M

NBIX

7.5%

Neurocrine Biosciences Inc.

$296.61M

VRTX

6%

Vertex Pharmaceuticals Inc

$239.14M

SAGE

5.5%

Sage Therapeutics, Inc.

$218.73M

13D/G large-stake context

MGNX

01 Jun 2025 · Common Stock

0%
Issuer page 13D/G history

AGIO

01 Jun 2025 · Common Stock

0%
Issuer page 13D/G history

BDTX

19 Mar 2025 · Common Stock

4.8%
Issuer page 13D/G history

ESPR

04 Mar 2025 · Common Stock

4.9%
Issuer page 13D/G history

Latest update

What changed recently for BB BIOTECH AG

New filing available

Latest 13F period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

15 May 2026

Page type

Filer profile

Latest period

Q1 2026

Institutional portfolio context was refreshed from a 13F filing filed on 15 May 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

BB BIOTECH AG has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000924223 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
59
First seen
12 Feb 2014
Latest filing
15 May 2026
Entity
Company

Observed form types

13F-HR 13F-NT SCHEDULE 13G/A

CIK-linked evidence first

BB BIOTECH AG SEC filings BB BIOTECH AG 13F portfolio BB BIOTECH AG 13D/G history Open SEC filing index

Latest Filings

Showing the latest 12 of 59 SEC filings for BB BIOTECH AG.

Open full filing history
13F-NT

13F-NT filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-NT

13F-NT filing

Filing date
17 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-NT

13F-NT filing

Filing date
14 Nov 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-NT

13F-NT filing

Filing date
14 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
13 Jun 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
13 Jun 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-NT

13F-NT filing

Filing date
14 May 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
21 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
10 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-NT

13F-NT filing

Filing date
14 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .